A
AcadiFi
Equity InvestmentsMedium

Windcrest Analytics observes that Novus Pharma has a trailing P/E of 22x, an expected earnings growth rate of 15%, and a PEG ratio of 1.47. Compared to its peer Helion Biotech, which has a PEG ratio of 0.90, which statement is most accurate?

CFA Level I — Equity Investments Practice Question | AcadiFi | AcadiFi